Trends in the global IVD market
This article was originally published in Clinica
The layman may think of success as being the attainment of wealth, status or fame, but, according to the Oxford English Dictionary, success is defined as the accomplishment of an aim or purpose. This suggests that to achieve success, a plan must be in place in order for it to come to fruition. None of the major in vitro diagnostic (IVD) companies would disagree with this concept, because more than ever before, they are prioritising the areas in which they wish to succeed. Such plans both respond to and create trends in the market. An area which particularly reflects this action and reaction phenomenon is the purchasing patterns of IVDs.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.